Home - Products - Angiogenesis - c-Met/HGFR - Capmatinib hydrochloride(free base)

Capmatinib hydrochloride(free base)

CAS No. 1029714-89-3

Capmatinib hydrochloride(free base)( INC280 | INCB28060 )

Catalog No. M21656 CAS No. 1029714-89-3

Capmatinib hydrochloride is a potent orally active selective and ATP competitive c-Met kinase inhibitor?potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 45 Get Quote
5MG 64 Get Quote
10MG 96 Get Quote
25MG 172 Get Quote
50MG 259 Get Quote
100MG 389 Get Quote
500MG 888 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Capmatinib hydrochloride(free base)
  • Note
    Research use only, not for human use.
  • Brief Description
    Capmatinib hydrochloride is a potent orally active selective and ATP competitive c-Met kinase inhibitor?potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).
  • Description
    Capmatinib hydrochloride is a potent orally active selective and ATP competitive c-Met kinase inhibitor?potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).
  • In Vitro
    Capmatinib (INCB28060) inhibits c-MET phosphorylation with an IC50 value of approximately 1 nM and a concentration of approximately 4 nM inhibits c-MET more than 90%, which isreversible and the effect is significantly reduced in several hours after the compound is removed and completely disappeared by 48 hours.Capmatinib (INCB28060) (0-10000 nM; 72 h) inhibits the proliferation of SNU-5, S114, H441 and U-87MG.Capmatinib (INCB28060) (0.06-62.25 nM; 2h) effectively inhibits phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5.Capmatinib (INCB28060) (0.24-63 nM; over night) prevents HGF-stimulated H441 cell migration.Capmatinib (INCB28060) (0.5-50 nM; 20 min) suppresses phosphorylation of both EGFR and HER-3 rapidly.Capmatinib (INCB28060) (0-333 nM; 24 h) induces apoptosis in SNU-5 cells. Cell Viability Assay Cell Line:SNU-5, S114, H441 and U-87MG Concentration:0-10000 nM Incubation Time:72 h Result:Inhibited the cell viability of SNU-5 and S114, as well as the colony formation of H441 and U-87MG, with IC50 values of 1.2 nM, 12.4 nM, ~0.5 nM and 2 nM, respectively.Cell Migration Assay Cell Line:H441 (stimulated with 50 ng/mL recombinant human HGF for 24h)Concentration:0.24, 1, 4, 16 and 63 nMIncubation Time:Over nightResult:Prevented HGF-stimulated H441 cell migration, with IC50 of approximately 2 nM, and less cell migration at 16 nM.Western Blot Analysis Cell Line:SNU-5 Concentration:0.06, 0.24, 0.98, 3.91, 15.63 and 62.25 nM Incubation Time:2 h Result:Effectively inhibited phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5.Western Blot Analysis Cell Line:H1993 cells Concentration:0.5, 5 and 50 nM Incubation Time:20 min Result:Suppressed phosphorylation of both EGFR and HER-3 rapidly and as effectively as the compound inhibited c-MET phosphorylation in H1993 cells.Apoptosis Analysis Cell Line:SNU-5 cellsConcentration:0.017, 0.15, 1.37, 12.33, 111 and 333 nM Incubation Time:24 h Result:Effectively induced DNA fragmentation.
  • In Vivo
    Capmatinib (INCB28060) (1-30 mg/kg; PO, twice daily, for 2 weeks) exhibits dose-dependent inhibition of tumor growth, and shows well tolerance at all doses during the treatment periods, with no evidence of overt toxicity or weight loss in U-87MG tumor mice model.Capmatinib (INCB28060) (0.03-10 mg/kg; PO, single dosage) causes inhibition of c-MET phosphorylation in S114 tumor mice model. Animal Model:Female Balb/c nu/nu mice (inoculated subcutaneously with 5×106 U-87MG glioblastoma cells)Dosage:1, 3, 10 and 30 mg/kg Administration:PO, twice daily, for 2 weeks Result:Exhibited dose-dependent inhibition of tumor growth with 35% and 76% at 1 and 3 mg/kg once daily; resulted in partial regressions in 6 of 10 U-87MG tumor-bearing mice at 10 mg/kg once daily; and showed well tolerance at all doses during the treatment periods, with no evidence of overt toxicity or weight loss. Animal Model:Female Balb/c nu/nu mice (inoculated subcutaneously with 4×106 S114 tumor cells) Dosage:0.03, 0.1, 0.3, 1, 3 and 10 mg/kg Administration:PO, single dosage Result:Caused approximately 50% and 90% inhibition of c-MET phosphorylation at 0.03 and 0.3 mg/kg after administration of 30 min, and inhibition of phospho-c-MET exceeded 90% after 7 hours.
  • Synonyms
    INC280 | INCB28060
  • Pathway
    Angiogenesis
  • Target
    c-Met/HGFR
  • Recptor
    c-Met
  • Research Area
    cancer
  • Indication
    cMET Dysegulation Advanced Solid Tumors

Chemical Information

  • CAS Number
    1029714-89-3
  • Formula Weight
    412.42
  • Molecular Formula
    C23H17FN6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Liu X Wang Q Yang G et al. A Novel Kinase Inhibitor INCB28060 Blocks c-MET-Dependent Signaling Neoplastic Activities and Cross-Talk with EGFR and HER-3[J]. Clinical Cancer Research 2011 17(22):7127-7138.
molnova catalog
related products
  • Capmatinib hydrochlo...

    Capmatinib hydrochloride is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF).

  • LMTK3-IN-1

    Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.

  • JNJ-38877618

    JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor.